Quick answer
Dr. Lukas Schneider is a European Clinical Development Editor for Europe & United Kingdom pharmaceutical intelligence editor on NovaPharmaNews, with 15 published articles covering EMA regulatory actions, clinical development, and market-moving news. Dr. Lukas Schneider brings 18 years of oncology development experience spanning trial operations and medical affairs. His coverage emphasizes EU study design trends, translational data quality, and cross-border development execution.
About Dr. Lukas Schneider
Dr. Lukas Schneider brings 18 years of oncology development experience spanning trial operations and medical affairs. His coverage emphasizes EU study design trends, translational data quality, and cross-border development execution.
Coverage focus
Topics and beats Dr. covers across Europe & United Kingdom.
Explore related intelligence
Entity directories linked from this author's coverage.
- Global markets Cross-region command center
- Company directory Sponsor & marketer profiles
- Drug profiles INN & regulatory status
- Clinical trials hub Stage & therapy filters
- Pipeline programs R&D intelligence
- Patent landscape US & EP IP moats
- Event calendar Congress catalysts
- Regulatory reference Submission types & pathways
Articles by Dr. Lukas Schneider
Biotheryx BTX-9341 Phase 1A Results to Be Presented at ESMO Breast Cancer Congress 2026
Biotheryx announces Phase 1A dose escalation study results for BTX-9341, a CDK4/6 degrader for HR+/HER2- breast cancer treatment at ESMO 2026.
Krystal Biotech Reports Strong Q1 2026 Results with VYJUVEK Global Expansion and Two Registrational Studies Pending
Krystal Biotech announces Q1 2026 results highlighting VYJUVEK global expansion and two upcoming registrational study readouts for gene therapy pipeline.
Biosimulation Market to Reach $11.3 Billion by 2031 as Pharmaceutical Companies Accelerate Digital Drug Development
The global biosimulation market will grow 16%+ annually to $11.3 billion by 2031, driven by pharmaceutical companies adopting digital modeling for faster drug development.
Stoke Therapeutics Zorevunersen Shows Promise for Dravet Syndrome Treatment Ahead of Q1 2026 Results
Stoke Therapeutics prepares Q1 2026 earnings call featuring Zorevunersen, an investigational antisense therapy targeting Dravet syndrome's underlying cause.
Emergent BioSolutions Reports Q1 2026 Financial Results: Biodefense Company Updates Revenue Performance
Emergent BioSolutions releases first quarter 2026 financial results, providing insights into the biodefense and pharmaceutical company's performance.
NMPA Conditional Approval Pathway: Impact on Innovative Oncology Drug Access
The NMPA Conditional Approval Pathway significantly enhances access to innovative oncology drugs, facilitating timely treatment options for cancer patients.
FDA Real-World Evidence Framework Shifts $10B Toward Validated Medtech Platforms Like VentriPoint
FDA's new real-world evidence requirements for medical devices create $10B market shift favoring established platforms with proven performance data.
GCC-DR Pharmaceutical Regulations: What You Need to Know
Learn about GCC-DR pharmaceutical regulations, essential for ensuring drug safety and compliance in the Gulf Cooperation Council region.
ANVISA Fast-Track Approvals: Key Changes for Oncology Drugs in Brazil
This article explores the recent key changes in ANVISA's fast-track approval process for oncology drugs in Brazil, focusing on improving patient access to vital treatments.
Bispecific Antibody Therapies in RRMM: Teclistamab & Emerging Trends (FDA 2025)
This article delves into Teclistamab, a bispecific antibody therapy for relapsed/refractory multiple myeloma (RRMM), and highlights emerging trends leading to FDA 2025.
AI-Driven Drug Discovery Partnership: Merck and Mayo Clinic Lead Innovation
Merck and the Mayo Clinic have launched a groundbreaking AI-driven drug discovery partnership. This collaboration aims to revolutionize pharmaceutical research by integrating artificial intelligence and clinical expertise to speed up new drug development.
Boston Scientific Corporation Faces Securities Class Action Lawsuit with May 4 Deadline for Investors
Boston Scientific investors have until May 4, 2026 to join securities class action lawsuit. Rosen Law Firm encourages shareholders to secure legal counsel.
EU Market Access ADCs: NICE, G-BA & HAS Assessments of Trastuzumab Deruxtecan
This article delves into the EU market access landscape for Trastuzumab Deruxtecan, focusing on assessments by NICE, G-BA, and HAS for HER2-positive cancers.
Pembrolizumab KEYNOTE-826 Trial: Expanded Use in Advanced Cervical Cancer
The KEYNOTE-826 trial highlights Pembrolizumab's promising role in treating advanced cervical cancer, offering new hope for patients.
EMA Issues Positive Opinion for Rexatilux (Ranibizumab) Eye Treatment
European Medicines Agency issues positive opinion for Rexatilux ranibizumab, advancing potential new eye treatment option for European patients.
Frequently asked questions
Who writes NovaPharmaNews articles?
Each story is attributed to a named editor or analyst with a public author profile. Profiles list credentials, coverage focus, and every published article so readers and AI systems can verify expertise and trace claims to a accountable journalist.
How do I find more coverage from this author?
Scroll to the article archive on this page, or use the topic chips linked from the author’s specializations. The regional authors directory lists every active contributor in this edition.
How does author coverage connect to companies and pipeline data?
Articles link to company profiles, drug INN pages, clinical trials, and pipeline programs when entities are tagged. Use the intelligence spokes on each story or browse topic hubs from the author’s beat.